Your browser doesn't support javascript.
loading
NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma.
Vegliante, Maria Carmela; Mazzara, Saveria; Zaccaria, Gian Maria; De Summa, Simona; Esposito, Flavia; Melle, Federica; Motta, Giovanna; Sapienza, Maria Rosaria; Opinto, Giuseppina; Volpe, Giacomo; Bucci, Antonella; Gargano, Grazia; Enjuanes, Anna; Tabanelli, Valentina; Fiori, Stefano; Minoia, Carla; Clemente, Felice; Negri, Antonio; Gulino, Alessandro; Morello, Gaia; Scattone, Anna; Zito, Alfredo F; Tommasi, Stefania; Agostinelli, Claudio; Vitolo, Umberto; Chiappella, Annalisa; Barbui, Anna Maria; Derenzini, Enrico; Zinzani, Pier Luigi; Casadei, Beatrice; Rivas-Delgado, Alfredo; López-Guillermo, Armando; Campo, Elias; Moschetta, Antonio; Guarini, Attilio; Pileri, Stefano A; Ciavarella, Sabino.
Afiliación
  • Vegliante MC; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Mazzara S; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Zaccaria GM; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • De Summa S; Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Esposito F; Department of Mathematics, University of Bari Aldo Moro, Bari, Italy.
  • Melle F; INDAM-GNCS Research Group, Rome, Italy.
  • Motta G; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Sapienza MR; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Opinto G; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Volpe G; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Bucci A; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Gargano G; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Enjuanes A; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Tabanelli V; INDAM-GNCS Research Group, Rome, Italy.
  • Fiori S; Unitat de Genòmica, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; CIBERONC, Barcelona, Spain.
  • Minoia C; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Clemente F; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Negri A; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Gulino A; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Morello G; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Scattone A; Cogentech srl Società Benefit, FIRC Institute of Molecular Oncology (IFOM), Milan, Italy.
  • Zito AF; Department of Health Sciences, Tumor Immunology Unit, University of Palermo School of Medicine, Palermo, Italy.
  • Tommasi S; Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Agostinelli C; Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Vitolo U; Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Chiappella A; Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Barbui AM; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
  • Derenzini E; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
  • Zinzani PL; Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Casadei B; Department of Oncology and Hematology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Rivas-Delgado A; Onco-Hematology Division, European Institute of Oncology IRCCS, Milan, Italy.
  • López-Guillermo A; Department of Health Sciences, University of Milan, Milan, Italy.
  • Campo E; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
  • Moschetta A; Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Guarini A; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
  • Pileri SA; Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Ciavarella S; CIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona; IDIBAPS, Barcelona, Spain.
Hematol Oncol ; 40(5): 864-875, 2022 Dec.
Article en En | MEDLINE | ID: mdl-35850118
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Hematol Oncol Año: 2022 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Hematol Oncol Año: 2022 Tipo del documento: Article País de afiliación: Italia